Tirzepatide research peptide
A 39-amino-acid fatty-diacid-modified peptide that agonises the GIP and GLP-1 receptors (development code LY3298176).
Sizes, prices and availability
| Size | SKU | Stated purity | Batch COA | Price | Availability | |
|---|---|---|---|---|---|---|
| 5 mg | TR5 | Not yet provided | Not yet provided | $16.99 | Out of stock | |
| 10 mg | TR10 | Not yet provided | Not yet provided | $19.99 | In stock | |
| 15 mg | TR15 | Not yet provided | Not yet provided | $21.99 | Out of stock | |
| 20 mg | TR20 | Not yet provided | Not yet provided | $24.99 | In stock | |
| 30 mg | TR30 | Not yet provided | Not yet provided | $30.99 | In stock | |
| 40 mg | TR40 | Not yet provided | Not yet provided | $36.99 | Out of stock | |
| 50 mg | TR50 | Not yet provided | Not yet provided | $44.99 | Out of stock | |
| 60 mg | TR60 | Not yet provided | Not yet provided | $53.99 | In stock | |
| 100 mg | TR100 | Not yet provided | Not yet provided | $72.99 | Out of stock |
Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details
About Tirzepatide
Tirzepatide (development code LY3298176) is a dual agonist of the GIP receptor and the GLP-1 receptor. It is a synthetic 39-amino-acid peptide with a fatty diacid side chain that supports binding to serum albumin.
A 2020 JCI Insight study found a greater degree of receptor engagement for the GIP receptor than for the GLP-1 receptor (an imbalanced agonist) and reported that at the GLP-1 receptor tirzepatide is biased toward cAMP generation over beta-arrestin recruitment, with weaker receptor internalisation than native GLP-1.
What the published literature covers
- Willard et al. (2020) describe tirzepatide as mimicking native GIP at the GIP receptor while showing signalling bias at the GLP-1 receptor.
- In primary islet experiments in the same study, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, which the authors link to the biased signalling of tirzepatide.
- Large clinical trial reports (SURPASS and SURMOUNT programmes) are available in the New England Journal of Medicine; two are listed below.
Vial arithmetic for Tirzepatide
Work out the concentration, syringe units per draw and draws per vial for any Tirzepatide vial size with our Tirzepatide reconstitution calculator, or the general peptide reconstitution calculator. To turn a volume into syringe units, use the syringe units converter. These tools do arithmetic only; they do not suggest any amount.
FAQ
Which receptors does tirzepatide act on?
Tirzepatide is a dual agonist of the GIP receptor and the GLP-1 receptor.
Is tirzepatide the same as semaglutide?
No. Semaglutide is a GLP-1 receptor agonist derived from the GLP-1 sequence, while tirzepatide is a dual GIP and GLP-1 receptor agonist. They are different molecules with different formulas.
What is the molecular formula of tirzepatide?
PubChem lists tirzepatide as C225H348N48O68 with a molecular weight of about 4813 g/mol.
What sizes of Tirzepatide does Covalume list?
Covalume lists Tirzepatide in 9 sizes: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 100 mg. Each size shows its price and live stock status in the variants table on this page.
How is the purity of Tirzepatide documented?
Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.
References
- Willard FS, Douros JD, Gabe MB, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5. PubMed 32730231 · DOI
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387:205-216. PubMed 35658024 · DOI
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385:503-515. PubMed 34170647 · DOI
Identity values are from PubChem (CID 166567236) and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-18.
Related research peptides
- Retatrutide Triple GIP, GLP-1 and glucagon receptor agonist peptide
- Semaglutide GLP-1 receptor agonist peptide analogue
- Cagrilintide Long-acting amylin analogue
- Survodutide Dual glucagon and GLP-1 receptor agonist peptide
- All glp-1 research peptides
From the research library
- Retatrutide vs tirzepatide: receptor targets
- Peptide purity: HPLC and mass spectrometry explained
- How to read a peptide Certificate of Analysis
- Peptide reconstitution: concentration and volume math
- Semaglutide vs tirzepatide: structure and receptors
- Peptide purity vs peptide content: a vial mass balance
- Check the mass spectrometry on a COA yourself
- How to read a COA HPLC chromatogram
- HPLC vs LC-MS for peptides: identity and purity workflow
- How to read an LC-MS trace: a worked peptide example
- TFA to acetate: peptide counter-ion exchange
- Peptide net charge, pI and solubility by pH
- Peptide adsorption to vials and plastics
- How long do peptides last? Stability evidence explained
- Bacteriostatic water vs sterile water